Your Health, We Care
Release date: 2024-07-10 15:05:18 Article From: Lucius Laos Recommended: 143
It is a receptor tyrosine kinase RET (Rearranged during Transfer) inhibitor used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with positive RET gene fusion; The treatment of advanced or metastatic RET mutant thyroid medullary carcinoma (MTC) in adults and children aged 12 and above who require systematic treatment, as well as advanced or metastatic RET fusion positive thyroid carcinoma in adults and children aged 12 and above who require systematic treatment and are refractory to radioactive iodine (if radioactive iodine is applicable).
At a grand pharmaceutical exhibition held recently in Dubai, Lucius Company of Laos was in the spotlight for its outstanding performance. Their booth attracted a large audience and···【more】
Recommended：210Release date: 2024-07-09
On October 18-19, 2023, Dr. Luís Meirinhos Soares, a microbiology expert appointed by the World Health Organization (WHO) and director of the Microbiology Laboratory of the Nationa···【more】
Recommended：224Release date: 2024-07-09
On October 19, 2023, the World Health Organization (WHO) conducted a comprehensive inspection of the Lucius Pharmaceutical factory in Laos. The results of this assessment are encou···【more】
Recommended：197Release date: 2024-07-09
At present, the competition in all walks of life is very fierce, especially in the pharmaceutical industry, Lucius Pharmaceutical was established in Vientiane, Laos in 2020, with a···【more】
Recommended：163Release date: 2024-07-09
Here are some key points about Lucius Pharmaceutical:Lucius Pharmaceuticals has state-of-the-art facilities, including factories designed and constructed in strict accordance with ···【more】
Recommended：294Release date: 2024-07-09
From the Black Sea, the most terrifying ocean on earth, to the Mediterranean Sea, Lucius Pharmaceuticals stands on the only Turkish Strait that connects the two seas, announcing Lu···【more】
Recommended：174Release date: 2024-07-09
As we all know, from the perspective of the universe, our solar system is very small, but from the perspective of the earth, it is very huge, the edge of the solar system is the Oo···【more】
Recommended：196Release date: 2024-07-09
At the beginning of May, Lucius Pharmaceutical (Laos) Co., Ltd. officially obtained the approval of the Ministry of Health of the People's Republic of China and launched 8 prod···【more】
Recommended：187Release date: 2024-07-09
The BRAF inhibitor known as Braftovi, manufactured by the French company pierre Fabre.What is the price of Braftovi per box? Where can it be purchased?Currently, there are two main···【more】
Recommended：263Release date: 2024-07-08
Dr. Louis, a microbiologist at the World Health Organization (WHO), recently made a technical visit to Lucius Pharmaceuticals in Laos. The purpose of the visit was to learn more ab···【more】
Recommended：332Release date: 2024-07-09
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and mortality, which has been troubling medical workers. Clinical studies have foun···【more】
Recommended：201Release date: 2024-07-09
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued favorable opinions, proposing an amendment to the mark···【more】
Recommended：158Release date: 2025-01-13
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced solid tumors, although further prospective research is still required. Historica···【more】
Recommended：156Release date: 2025-01-06
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administration (FDA) has given the green light to the first generic version of Victoza (···【more】
Recommended：171Release date: 2024-12-30
The new indication involves the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer with tumors with EGFR exon 19 deletion or exon 21 (L858R)···【more】
Recommended：161Release date: 2024-12-24
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combination with glucocorticoids (steroids) to help manage androgen (testosterone-like ···【more】
Recommended：146Release date: 2024-12-17
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, obecabtagene autoleucel, demonstrated a high res···【more】
Recommended：105Release date: 2024-12-13
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) gave a positive recommendation for the approval of toripalimab (brand name Lo···【more】
Recommended：248Release date: 2024-08-26
On June 27, 2024, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use issued a favorable opinion recommending the approval of a marketing autho···【more】
Recommended：192Release date: 2024-08-19
On August 2, 2024, the FDA granted accelerated approval to afamitresgene autoleucel, marking the first gene-engineered T-cell therapy approved for the treatment of solid tumors. Th···【more】
Recommended：207Release date: 2024-08-12
On June 14, 2024, the US Food and Drug Administration (FDA) granted approval for blinatumomab (Blincyto, Amgen Inc.) to be used in the consolidation phase of multiphase chemotherap···【more】
Recommended：207Release date: 2024-08-07
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. For patients with advanced or metastatic NSCLC, partic···【more】
Recommended：243Release date: 2024-08-05
On June 26, 2024, the Food and Drug Administration (FDA) granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3 T-cell engager,···【more】
Recommended：196Release date: 2024-08-01
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended：1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended：1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended：1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended：1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended：1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended：1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended：2482024-26-08
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
